The C1GALT1 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Jurkat T lymphocyte cell line, designed to disrupt the C1GALT1 gene encoding glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1, also known as core 1 synthase. This targeted gene knockout model serves as a loss-of-function system to investigate the biological consequences of C1GALT1 deficiency in T cells, particularly its essential role in the initiation of mucin-type O-glycosylation. The polyclonal population comprises a mixture of Jurkat cells with heterogeneous CRISPR/Cas9-mediated gene disruptions, providing a robust cellular tool for studying O-glycan biosynthesis and its impact on immune cell function without necessitating clonal selection.
The parental Jurkat cell line is an immortalized human T lymphocyte line originally established from the peripheral blood of a 14-year-old male with T cell leukemia. Jurkat cells are extensively utilized as a model system for TCR signaling, T cell activation, apoptosis, and leukemia biology due to their indefinite proliferative capacity and well-characterized signaling pathways. This host cell background is particularly relevant for glycosylation research because T cell surface receptors, including CD3, CD4, CD8, and the TCR complex, are heavily glycosylated, and alterations in O-glycan structures can profoundly influence T cell development, activation, and immune recognition.
C1GALT1 catalyzes the transfer of galactose from UDP-galactose to N-acetylgalactosamine (GalNAc) residues linked to serine or threonine on proteins, forming the core 1 O-glycan (Gal??1-3GalNAc), which is the predominant core structure of mucin-type O-glycans. The activity of C1GALT1 is strictly dependent on the endoplasmic reticulum-localized chaperone COSMC, an upstream regulator that ensures correct folding and functional expression of the enzyme. In the absence of functional C1GALT1, O-glycan elongation is arrested, leading to the accumulation of the truncated Tn antigen (GalNAc-Ser/Thr) on glycoproteins. Key downstream targets modified by C1GALT1-dependent glycosylation include the mucin MUC1, the transmembrane glycoproteins CD43 and CD45, and the P-selectin glycoprotein ligand 1 (PSGL-1), all of which are important for T cell adhesion, migration, and signaling. Representative components of this glycosylation pathway include N-acetylgalactosaminyltransferases (GALNTs) that initiate O-glycosylation, C1GALT1 for core 1 formation, COSMC as the obligatory chaperone, and downstream sialyltransferases such as ST3Gal1 and fucosyltransferases that further elaborate the glycan chains.
Disruption of C1GALT1 in Jurkat T cells recapitulates the glycosylation defect observed in Tn syndrome, a rare hematologic disorder characterized by clonal expansion of blood cells expressing the Tn antigen. In this model, loss of core 1 O-glycans leads to aberrant exposure of Tn antigen on cell surface receptors, potentially altering T cell activation thresholds, intracellular signaling cascades, and interactions with galectins and other glycan-binding proteins. Moreover, the C1GALT1 knockout Jurkat cells serve as a relevant platform for cancer glycobiology, since many epithelial and hematologic malignancies exhibit deregulated C1GALT1 expression and Tn antigen accumulation, which are associated with tumor progression and immune evasion. By eliminating core 1 O-glycans in a T lymphocyte context, researchers can dissect the molecular mechanisms by which O-glycosylation regulates immune receptor function and contributes to immunodeficiencies and leukemogenesis.
This polyclonal knockout product is suitable for a broad range of downstream applications, including lectin-based detection of glycan changes using peanut agglutinin (PNA, which binds core 1 structures) and Vicia villosa lectin (VVL, which recognizes Tn antigen), flow cytometric analysis of glycosylation-dependent epitopes, western blotting to assess shifts in glycoprotein molecular weight, T cell activation assays to evaluate functional consequences of aberrant O-glycosylation, and O-glycan profiling by mass spectrometry. The C1GALT1 Knockout Jurkat Polyclonal Cells thus provide a versatile tool for dissecting the role of mucin-type O-glycosylation in T cell biology, cancer immunotherapy, and the development of glycoprotein therapeutics. For additional technical information, assay recommendations, or purchasing inquiries, please contact Ascent Research.
